logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5655.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5655.produseast1
Showing 1 - 6 of 6 Items
Showing 1 - 6 of 6 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R,  et al.
2025-02-01 • Lancet Child and Adolescent Health
2025-02-01 • Lancet Child and Adolescent Health

BACKGROUND

There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially ...

Journal Article
|
Research
Conference Material
|
Slide Presentation
Conference Material
|
Abstract
Journal Article
|
Letter

Reduced critical concentration might not have improved MGIT-based DST’s sensitivity to rifampicin

Technical Report
|
Study report

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country MDR/RR-TB cohort

Khan U, Rich M, Franke M, Lachenal N, Ahmed S,  et al.
2024-12-10 • Clinical Infectious Diseases
2024-12-10 • Clinical Infectious Diseases

BACKGROUND

The 2022 WHO guidelines on multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) recommend six months of bedaquiline (Bdq) in the all-oral 9-month shorter regimen ...

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Lachenal N,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Lachenal N,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
INTRODUCTION
Tuberculosis (TB) is a major public health challenge encountered across many Médecins Sans Frontières (MSF) fields. Management of drug-resistant TB is an operational pri...
Rupasinghe P, 
Ashraf A, 
Barreda N, 
Parveen S, 
Zubair M, 
et al.
2024-05-02 • Antimicrobial Agents and Chemotherapy
2024-05-02 • Antimicrobial Agents and Chemotherapy

endTB interim analysis report - Bedaquiline- and delaminid- containing regimens achieve excellent interim treatment response without safety concerns

Atwood S, Avagyan N, Bastard M, Cain M, Collin S,  et al.
2018-07-01
2018-07-01